ARTICLE | Clinical News
Antisoma plunges after misses in AML
February 1, 2011 1:13 AM UTC
Antisoma plc (LSE:ASM) fell 4.03p (64%) to 2.22p on Monday after announcing that it discontinued development of acute myelogenous leukemia (AML) candidate amonafide ( AS1413). The decision came after ...